Eyevensys

High-Level Overview

Eyevensys is a Paris-based, clinical-stage biotechnology company founded in 2008, specializing in a first-in-class, non-viral gene therapy platform for sustained drug delivery to treat major ophthalmic conditions like degenerative retinal diseases (e.g., wet and dry AMD), retinal vascular diseases, non-infectious uveitis, retinitis pigmentosa, and glaucoma[1][2][3][6]. The platform uses electroporation to deliver DNA plasmids into the ciliary muscle, enabling long-term intraocular production of therapeutic proteins such as anti-TNF (EYS606), anti-VEGF (EYS609), and neuroprotective agents (EYS611), addressing vision loss affecting millions globally by avoiding frequent injections, subretinal delivery, or implants[1][3][5]. It serves patients with blinding eye diseases, ophthalmologists, and the biotech ecosystem, with early clinical validation in uveitis and preclinical efficacy across models; the company raised funding from investors like Korea Investment Partners, Bpifrance, and Karista VC[1][2].

Note: Eyevensys pivoted and relaunched as PulseSight Therapeutics in 2024, retaining its core technology and IP to target dry AMD with PST-611 entering Phase I, driven by a COVID-induced pause that shifted focus to higher-market opportunities[2][8].

Origin Story

Eyevensys was founded in 2008 by Francine Béhar-Cohen, MD, PhD, a vitreoretinal surgeon and INSERM researcher with 23+ years studying ocular disease pathophysiology; she previously founded EyeGate Pharma[2][5]. The idea stemmed from her work developing electroporation-based delivery of DNA plasmids to the ciliary muscle for sustained protein production in the vitreous, initially targeting severe non-infectious uveitis after preclinical success in animal models (rats, rabbits) showing durable expression of anti-VEGF, anti-TNF, and neuroprotective proteins[2][3]. Early traction included clinical validation of the electro-transfection platform for uveitis (EYS606 in trials by 2019-2020), FDA-compliant device testing, and recognition in France's Tech 120 program[3][5][6]. Patricia Zilliox served as President & CEO around 2019, showcasing the pipeline at events like OIS@ASRS[3]. The COVID-19 pause led to a 2024 pivot to PulseSight under new CEO Judith Greciet, prioritizing dry AMD[2].

Core Differentiators

• Non-viral gene therapy platform: Uses safe electroporation (no viruses) to inject plasmids into ciliary muscle for sustained, on-site protein production (e.g., anti-TNF, anti-VEGF, neuroprotectants), proven durable in multiple animal models without safety issues[1][2][3][5].
• Minimally invasive delivery: Avoids subretinal/intraocular injections, implants, or systemic dosing; single administration enables long-term therapy, reducing patient burden for chronic conditions like AMD and uveitis[1][3].
• Broad pipeline applicability: Validated for diverse proteins/indications (uveitis in clinic, preclinical for wet/dry AMD, RP, glaucoma, DME); flexible for gene transference, TNF-α inhibitors, and more[3][6].
• Clinical momentum: Early human data in uveitis; PulseSight advancing PST-611 to Phase I for dry AMD, building on Eyevensys' IP and expertise[2][6].

Role in the Broader Tech Landscape

Eyevensys rides the wave of gene therapy innovation in ophthalmology, where retinal diseases like AMD drive majority of global vision loss, amid surging demand for durable, injection-free treatments amid aging populations and limitations of anti-VEGF standards (frequent dosing, poor dry AMD options)[1][2][3]. Timing aligns with non-viral tech maturation—electroporation offers viral vector alternatives' benefits (sustained efficacy) minus risks like immunogenicity, fitting post-COVID biotech pivots to high-value indications[2]. Market tailwinds include $20B+ AMD space, regulatory nods for gene therapies (e.g., Luxturna), and France's strong medtech ecosystem via INSERM/Bpifrance[1][5]. It influences by validating ciliary muscle as a "biofactory," potentially enabling platforms for other back-of-eye diseases and inspiring non-viral shifts.

Quick Take & Future Outlook

Eyevensys' legacy endures via PulseSight, with Phase I dry AMD data as the pivotal near-term catalyst to de-risk the platform and attract partners/big pharma[2][8]. Trends like AI-optimized plasmids, combo therapies, and global AMD prevalence will propel it, potentially expanding to wet AMD/RP trials using EYS609/EYS611 assets. Influence may grow through licensing or acquisition, transforming it from uveitis pioneer to retinal gene therapy leader—watch for 2026 readouts tying back to its factory-like delivery solving injection fatigue.